We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > fevipiprant

News List

Novartis Will Not Support Further Development of Fevipiprant for Asthma americanpharmaceuticalreview
December 18, 2019
Novartis announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily ...
Novartis’ fevipiprant fails to meet clinically relevant threshold in phase III asthma studies pharmaceutical-business-review
December 17, 2019
Novartis announced that its asthma treatment fevipiprant has failed to meet the clinically relevant threshold in Luster phase III studies.
World Asthma Day: can fevipiprant revolutionise asthma treatment? pharmaceutical-technology
May 07, 2019
World Asthma Day aims to raise awareness of the burden of asthma. Increasingly, the standard of care for asthma, reliever and preventer inhalers, are being discovered to be insufficient in a number of ways.